Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 2, 2005, Pages 193-205

  Esposti, Luca Degli ^a   Di Martino, Mirko ^a   Saragoni, Stefania ^a   Capone, Alessandro ^a   Russo, Pierluigi ^b   Esposti, Ezio Degli ^c  

^a Department of Critical Area ^*

^b UNIVERSITY OF FLORENCE   (Italy)

^c Local Health Authority of Ravenna   (Italy)

Author keywords

Adherence with treatment; Administrative databases; Cost offset analysis; Lipid lowering drugs; Pharmacoeconomics

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE;

AGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG UTILIZATION; ECONOMIC EVALUATION; GENDER; HOSPITAL COST; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY PREVENTION; RESOURCE ALLOCATION; REVIEW; SECONDARY PREVENTION;

EID: 17544382168     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.2.193     Document Type: Review

References (28)

1. American Heart Association. 2004 Heart and stroke statistical update. Dallas, TX, USA. American Heart Association (2004).
2. American Heart Association. 2003 Heart and stroke statistical update. Dallas, TX, USA. American Heart Association (2003).
3. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor intervention trial. Prev. Med. 15, 254-273 (1986).
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials Results. I: reduction in incidence of coronary heart disease. JAMA 251, 351-364 (1984).
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials Results. II: the relationship of reduction in incidence of coronary heart disease to cholesterol-lowering. JAMA 251, 365-374 (1984).
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study. Lancet 344, 1383-1389 (1994).
7. Sacks FM, Pfeffer MA, Moye LA et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
8. The long term intervention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
9. Downs JR, Clearfield M, Weis M et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level: results of AFCAPS/TexCAPS. JAMA 279, 1615-1622 (1998).
10. Sheperd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
12. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
13. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 279(18), 1458-1462 (2002).
14. Jackevicius CA, Mamdani M, Tu JV. Adherence to statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288(4), 462-467 (1998).
15. Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288(4), 455-461 (2002).
16. Degli Esposti L, Di Martino M, Saragoni S et al. Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data. Ital. Heart J. 5(2), 120-126 (2004).
17. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur. Heart J. 18(10), 1569-1582 (1997).
18. EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. 22(7), 554-572 (2001).
19. Hughes DA, Bagust A, Haycox A et al. Accounting for noncompliance in pharmacoeconomic evaluations. PharmacoEconomics 19(12), 1185-1197 (2001).
20. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. PharmacoEconomics 15(3), 217-228 (1999).
21. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur. Heart J. 17(Suppl. A), 8-15 (1996).
22. Anatomic Therapeutical Chemical Classification. L'Informatore Farmaceutico. 59th Edition. Organizzazione Editoriale Medico Farmaceutica, Milan, Italy (1999).
23. International Classification of Diseases - 9th Revision. World Health Organization, Geneva, Switzerland (1977).
24. DRGs and healthcare. In: The Management of Case Mix. Bardsley M, Coles J, Jenkins L (Eds). King Edward's Hospital Fund, London, UK (1987).
25. SPSS Inc. for Windows version 11.5. Chicago, IL, USA (2002).
26. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Br. Med. J. 321, 1-5 (2000).
27. Motheral BR, Fairman KA. The use of claims databases for outcome research: rational challenges and strategies. Clin. Ther. 19(2), 346-366 (1998).
28. Relman AS. Assessment and accountability. The third revolution in medical care. N. Engl. J. Med. 319(18), 1220-1222 (1997).